Nano commercialisation update
Filed with ASX · · 1 page · English
Earlier from Micro-X
- Appendix 4D and Half Year Financial Report
- Nano Commercialisation - First From Production Acceptance
- Appendix 4E and 2017 Annual Report
- R&D tax rebate
- Carestream receives FDA 510(k) Approval for Nano
Later from Micro-X
- Successful completion of $5.0M capital raising
- R&D contract signed with UK ministry of Defence
- Expected impairment charge
- Expected impairment charge clarification
- Appendix 4E and 2018 Annual Report
Follow Micro-X into a list and get an email when it puts out news.
Follow Micro-X